Industry News
Pharmaceutical Industry News
GLP-1s, AI and telemedicine are…
GLP-1s, AI and telemedicine are changing patient behavior. Learn what it means for diagnosis, engagement and commercialization.
Abbott is again tapping into the…
Abbott is again tapping into the competitive spirit of Big Ten universities to drive blood donations, pitting the schools against each other in pursuit of a $1 million prize amid a national supply crisis.
Roughly a year and a half after…
Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential concerns about the safety of the rare
Legend Biotech’s interim CEO, Alan…
Legend Biotech's interim CEO, Alan Bash, discusses competition from T-cell engagers and Gilead's new autologous CAR-T as the Carvykti maker posted its first profitable quarter.
Alfasigma will add key drugs like…
Alfasigma will add key drugs like Nordimet through the deal, as well as Nordic Pharma’s women’s health, critical care and ophthalmology portfolios.
Eli Lilly has filed lawsuits…
Eli Lilly has filed lawsuits against six U.S. companies, accusing them of selling illegal versions of its experimental weight-loss drug retatrutide.
Shortly after initiating a…
Shortly after initiating a separate recall tied to mislabeled pain medicine, Fresenius Kabi is yanking a batch of another product in the U.S.
Snapchat is courting pharma…
Snapchat is courting pharma marketers with a new ad format designed to support the disclosure needs of branded prescription drug campaigns.
In the second quarter, nine of the…
In the second quarter, nine of the world's top 25 drugmakers accomplished double-digit revenue increases, led again by Eli Lilly, which charted a 48% sales gain. The revenue boom was even more pronounced when comparing
Despite their divergent…
Despite their divergent second-quarter performance against consensus estimates, BridgeBio and Alnylam are now targeting the same population—first-line ATTR-CM patients—as the silencer-vs-stabilizer debate drags on.
Arguing that the Defense…
Arguing that the Defense Department might have misread the evidence and inflicted harm on the company, a federal judge has thrown WuXi AppTec a lifeline as the research and manufacturing services juggernaut fights its recent
President Donald Trump signed an…
President Donald Trump signed an executive order Monday that calls for reducing the number of required vaccinations for children in a move that backs a revised immunization schedule pushed by the Department of Health and
Nearly three decades after its…
Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a decisive clinical win to enter the U.S. market.
The FDA has denied ITM Isotopes…
The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.
Abbott has enlisted telenovela…
Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have to be dramatic.
Bristol Myers Squibb has laid out…
Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.
Scholar Rock has dropped Novo…
Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of the plant was classified as “Official
Quanterix has hired medtech…
Quanterix has hired medtech veteran Jim Gute as chief commercial officer, bringing him over from Exact Sciences after an earlier 18-year career at GE Healthcare.
A Generation on Antidepressants Searches for the Exit
Many people feel that antidepressants block their true emotions, but they don’t have guidance about how to get off these drugs.
Injected weight loss drugs remain…
Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix Global Insights.